Loading
Heart Failure Treatment and Management · Journal article
Medical Journal of Cell Biology · July 1, 2026
Well-designed and adequately powered for the question it asks.
This is a narrative review synthesizing pathophysiology and evidence for iron deficiency in heart failure and cardiovascular disease. Intravenous iron, particularly ferric carboxymaltose, shows consistent clinical benefits across multiple RCTs (FAIR-HF, IRONMAN, HEARTFID, FAIR-HF2) in reducing hospitalization, improving functional capacity and symptoms, and has been endorsed by the European Society of Cardiology 2023 with strongest recommendation for symptomatic reduced or mid-range ejection fraction heart failure.
Narrative review summarizing evidence from multiple RCTs. Heart failure patients (all ejection fraction subtypes) and cardiovascular disease patients with iron deficiency. Intervention: Intravenous iron, particularly ferric carboxymaltose. Compared with: Placebo (referenced for six-minute walk distance endpoint); oral iron (compared indirectly).
Iron deficiency affects 40–80% of heart failure patients across all ejection fraction subtypes. Around 60% of coronary artery disease patients have iron deficiency, raising ischemic events. Pulmonary hypertension prevalence of iron deficiency is 40–60%, shortening six-minute walk distance.
Cost-effectiveness, long-term safety profile, and optimal dosing schedules not discussed in source.
Clinicians should consider routine iron screening in symptomatic heart failure and treat with intravenous iron (ferric carboxymaltose) according to 2023 ESC guidelines with strongest recommendation for rEF and mEF subtypes, as evidence supports meaningful reductions in hospitalization and improvement in functional capacity and quality of life.
High-quality evidence from multiple named RCTs (FAIR-HF, IRONMAN, HEARTFID, FAIR-HF2) demonstrating consistent clinical benefits of intravenous iron across objective endpoints (LVEF, functional capacity, hospitalization) and endorsed by major guideline bodies with strongest recommendation.
As stated by the source record.
Quoted from the source exactly as published.
Clinicians should consider routine iron screening in symptomatic heart failure and treat with intravenous iron (ferric carboxymaltose) according to 2023 ESC guidelines with strongest recommendation for rEF and mEF subtypes, as evidence supports meaningful reductions in hospitalization and improvement in functional capacity and quality of life.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Abstract Iron deficiency affects 40-80% of heart failure patients – across reduced, mid-range, and preserved ejection fraction subtypes – worsening exercise intolerance, frailty, quality of life, hospitalization rates, and mortality, regardless of anemia presence. This review examines iron deficiency’s central role in oxygen metabolism, mitochondrial energy production (adenosine triphosphate), and cellular respiration; its strong links to coronary artery disease (around 60% prevalence, raising ischemic events and impairing heart muscle remodeling after infarction) and pulmonary hypertension (40-60% prevalence, shortening six-minute walk distance, elevating pulmonary pressures, and harming right heart function); diagnostic hurdles during inflammation; and evidence-driven treatment strategies. Inflammation boosts hepcidin, a hormone that traps iron inside cells by breaking down ferroportin, starving heart muscle cells of energy and forcing reliance on inefficient anaerobic metabolism. Intravenous iron, such as ferric carboxymaltose, consistently delivers gains: better left ventricular ejection fraction, New York Heart Association symptom class, six-minute walk distance (plus 45 meters versus placebo), and quality-of-life scores (EQ-5D or Minnesota questionnaires), alongside 20-30% drops in heart failure hospitalizations from major trials like FAIR-HF, IRONMAN, HEARTFID, and FAIR-HF2. Oral iron falls short due to poor uptake in inflamed conditions. European Society of Cardiology 2023 guidelines urge routine screening and intravenous iron for symptomatic reduced or mid-range ejection fraction heart failure (strongest recommendation, high-quality evidence), with growing support for preserved ejection fraction and pulmonary hypertension cases.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.